PEG-Hb Conjugate Stabilization via Antioxidant Addition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing hemoglobin-based oxygen carriers (HBOCs) face challenges such as short circulation half-life, toxicity, vasoconstriction, and high auto-oxidation rates, particularly in deoxygenated PEG-Hb conjugates stored at low or ambient temperatures.
Innovation Solution
A method involving deoxygenation of PEG-Hb conjugates followed by the addition of antioxidants like N-acetyl cysteine (NAC) and NADPH to reduce auto-oxidation rates, resulting in a stabilized PEG-Hb conjugate with enhanced stability and reduced methemoglobin formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If deoxygenated PEG-Hb conjugate solutions are prepared and stored at low or ambient temperatures, then oxygen carrier stability is improved, but auto-oxidation rates increase leading to methemoglobin formation
Solution Approach 1:
Ascorbate acts as an intermediary substance that mediates between the deoxygenated PEG-Hb conjugate and oxygen, preventing direct oxidation of the hemoglobin iron. The ascorbate donates electrons to reduce ferric iron back to ferrous iron, thereby preventing methemoglobin formation while allowing the solution to be stored at ambient temperatures.
Solution Approach 2:
The invention changes the chemical composition parameter by adding ascorbate to the PEG-Hb conjugate solution. This parameter change fundamentally alters the oxidation-reduction balance of the system, enabling stable storage at higher temperatures by preventing the auto-oxidation that would otherwise occur.
2Duration of action of moving object
If PEG conjugation is used to increase hydrodynamic size and prevent extravasation, then circulation half-life is extended, but auto-oxidation susceptibility increases
Solution Approach 1:
Ascorbate serves as a protective intermediary that specifically addresses the increased auto-oxidation susceptibility introduced by PEG conjugation. The ascorbate molecules surround and protect the PEG-Hb conjugate from oxidative damage, allowing the benefits of extended circulation half-life to be realized without the harmful effects of rapid auto-oxidation.
3Duration of action of moving object
If cross-linking is used to prevent dimer formation and increase half-life, then circulation duration is extended, but oxygen affinity increases which may prevent effective oxygen delivery
Solution Approach 1:
Instead of using permanent cross-linking modifications that alter the fundamental properties of hemoglobin, the invention uses a temporary, reversible approach with ascorbate. The ascorbate provides the necessary stability during circulation without permanently modifying the hemoglobin structure, allowing normal oxygen affinity to be maintained.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized PEG-Hb conjugate exhibits improved stability at various temperatures for extended periods, maintaining low oxygen affinity and preventing oxidative damage, thus addressing the limitations of existing HBOCs.
Implementation Method 1
adding one or more antioxidants during or following the deoxygenating step to form a stabilized PEG-Hb conjugate
Data Source
AI summary
The present invention is a method for preparing stable HBOC solutions. Specifically, the method comprises the steps of deoxygenating a PEG-Hb conjugate and adding one or more antioxidants during or following the deoxygenating step to form a stabilized PEG-Hb conjugate. The Hb in the PEG-Hb conjugate is not crosslinked and the stabilized PEG-Hb conjugate has a p50 less than that of native SFH from the same animal source when measured under the same conditions. Specifically, the p50 is 6±2 mmHg or less than 10 mmHg.